Profile picture of Chun Loo Gan

Dr Chun Loo Gan

Profile picture of Chun Loo Gan

MBBS, MCncrSc, FRACP

Medical Oncologist
Call
Email
Referrals

Dr Chun Loo Gan understands the importance of patient-centred care and is committed to providing expert personalised cancer care to his patients and their loved ones. He speaks fluent English and Mandarin, and understands a variety of Chinese dialects including Cantonese and Hokkien. Dr Gan looks forward to supporting patients in a language they are familiar with.

Biography

Dr Chun Loo Gan is an Australian trained medical oncologist at Icon Cancer Centre Chermside and Icon Cancer Centre Greenslopes. In 2011 he completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at the University of Melbourne and subsequently undertook basic physician training at the Royal Melbourne Hospital. Dr Gan later commenced advanced medical oncology training at Monash Medical Centre and Olivia Newton-John Cancer Centre in Melbourne, Victoria. He undertook a 12-month clinical trial fellowship at Monash Health Translation Precinct and became a Fellow of the Royal Australasian College of Physicians in 2018.

Dr Gan is a strong advocate for research and clinical trials with a particular interest in genitourinary and gastrointestinal cancers and melanoma. In 2019 he completed a two-year genitourinary oncology fellowship at the Tom Baker Cancer Centre in Calgary, Canada, under the supervision of Prof. Daniel Heng, the founder of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). As the IMDC fellow, Dr Gan led multiple international collaborative research studies in advanced renal cell carcinoma and immunotherapy. He presented his research work at international and national meetings and received several awards including two prestigious Merit Awards from the American Society of Clinical Oncology and the Novartis Oncology Young Canadian Investigator Award. Dr Gan has also completed a Masters in Cancer Sciences at the University of Melbourne with a particular focus in cancer immunotherapy.

Dr Gan can converse in English and Mandarin, and looks forward to supporting patients in a language they are familiar with. His clinical experience covers a broad range of solid tumour malignancies with a special interest in gastrointestinal cancer, genitourinary cancer and melanoma.

Publications

  • Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. C.L. Gan, I. Stukalin, D.E. Meyers, S. Dudani, H.A.I. Grosjean, S. Dolter, B.W. Ewanchuk, S. Goutam, M. Sander, C. Wells, A. Pabani, T. Cheng, J. Monzon, D. Morris, N.S. Basappa, S.K. Pal, L.A. Wood, F. Donskov, T.K. Choueiri & D.Y.C Heng. European Journal of Cancer, 2021; 151: 115-125.

  • New insights into the obesity paradox in renal cell carcinoma. C.L. Gan CL & D.Y.C Heng. Nature Reviews Nephrology, 2020; 16(5): 253-254.

  • Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma: Current Perspective and a Look Into the Future. C.L. Gan, S. Dudani & D.Y.C Heng. The Cancer Journal, 2020; 26(5): 365-375.

  • Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. C.L. Gan, S. Dudani, J.C. Wells, F. Donskov, S.K. Pal, N. Dizman, N. Rathi, B. Beuselinck, F. Yan, A.-K.A Lalani, A. Hansen, B. Szabados, G. de Velasco, B. Tran, J.L. Lee, U.N. Vaishampayan, G.A. Bjarnason, M. Subasri, T.K. Choueiri & D.Y.C. Heng, D.Y.C. Cancer Medicine, 2021; 10: 1212-1221.

  • Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. N.A. Bosma, M.T. Warkentin, C.L. Gan, S. Karim, D.Y.C. Heng, D.R. Brenner & R.M. Lee-Ying. European Urology Open Science, 2022; 37: 14-26.

Special Interests

Dr Chun Loo Gan accepts referrals for all cancer types, with a special clinical interest in:

  • Gastrointestinal cancer
  • Genitourinary cancer
  • Melanoma

Languages Spoken

  • Cantonese
  • English
  • Malay
  • Mandarin

Visiting Locations

  • Royal Brisbane and Women’s Hospital
  • Greenslopes Private Hospital

Affiliations & Memberships

  • Australasian Gastro-Intestinal Trials Group(AGITG)
  • Australian and New Zealand Urogenital & Prostate Cancer Trials Group (ANZUP)
  • American Society of Clinical Oncology (ASCO)
  • Medical Oncology Group of Australia (MOGA)
  • Royal Australasian College of Physicians (RACP)

Publications

  • Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. C.L. Gan, I. Stukalin, D.E. Meyers, S. Dudani, H.A.I. Grosjean, S. Dolter, B.W. Ewanchuk, S. Goutam, M. Sander, C. Wells, A. Pabani, T. Cheng, J. Monzon, D. Morris, N.S. Basappa, S.K. Pal, L.A. Wood, F. Donskov, T.K. Choueiri & D.Y.C Heng. European Journal of Cancer, 2021; 151: 115-125.

  • New insights into the obesity paradox in renal cell carcinoma. C.L. Gan CL & D.Y.C Heng. Nature Reviews Nephrology, 2020; 16(5): 253-254.

  • Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma: Current Perspective and a Look Into the Future. C.L. Gan, S. Dudani & D.Y.C Heng. The Cancer Journal, 2020; 26(5): 365-375.

  • Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. C.L. Gan, S. Dudani, J.C. Wells, F. Donskov, S.K. Pal, N. Dizman, N. Rathi, B. Beuselinck, F. Yan, A.-K.A Lalani, A. Hansen, B. Szabados, G. de Velasco, B. Tran, J.L. Lee, U.N. Vaishampayan, G.A. Bjarnason, M. Subasri, T.K. Choueiri & D.Y.C. Heng, D.Y.C. Cancer Medicine, 2021; 10: 1212-1221.

  • Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. N.A. Bosma, M.T. Warkentin, C.L. Gan, S. Karim, D.Y.C. Heng, D.R. Brenner & R.M. Lee-Ying. European Urology Open Science, 2022; 37: 14-26.

Search

Become a patient